View
215
Download
0
Category
Preview:
Citation preview
European Journal of Pain (1997) 1: 161-164
Short Communication
Morphine-3-glucuronide prevents tolerance to morphine-6-glucuronide in mice
C. C. Fauraarb, M. J. Olasoa and J. F. Horgaapb
aDepartamento de Farmacologia y Terapbutica and blnstituto de Neurociencias, Universidad Miguel Hernandez, Alicante, Spain
Daily subcutaneous (SC.) pretreatment with morphine-3-glucuronide (6 mg/kg) was found to reduce morphine- 6-glucuronide (4mg/kg s.c.)-induced antinociception, with no decrease in the effect over 5 days. Morphine-6- glucuronide administration (4 mg/kg s.c.) on Day 6, without morphine-3-glucorinide pretreatment, results in a significant increase in antinociception (from 24% on Day 5 to 70%; ~~0.05). Morphine-3-glucuronide may prevent tolerance to morphine-6-glucuronide by reducing morphine-6-glucuronide-induced antinociception.
INTRODUCTION
Morphine-6-glucuronide (M6G), the most im- portant active metabolite of morphine, binds to the p-opioid receptor, has a more potent anti- nociceptive effect than morphine and tolerance to this effect has also been proved (Faura et al., 1996). The major morphine metabolite, mor- phine-3-glucuronide (M3G), shows no affinity for the p-opioid receptor and has no analgesic activity; however, there are conflicting reports of its effects on morphine and M6G pharmacology (Smith et al., 1990; Gong et al., 1992; Ekblom et al., 1993; Faura et al., 1996).
Previously, the authors have shown that the acute antinociceptive effect of systemically ad- ministered M6G (4 mg/kg) was antagonised by M3G (6mg/kg) without affecting the anti- nociception induced by equipotent doses of mor- phine (lOmg/kg, Faura et al., 1996). Based on the above data, the aim of this study was to evalute if the reduction of the antinociceptive effect of M6G by M3G is followed by a decrease in the degree of tolerance to M6G.
Paper received 5 March 1997 and accepted in revised form 17 June 1997. Correspondence to: C. C. Faura, Departamento de Farmacologia TerapCutica, Universidad Miguel Hernandez, Campus de San Juan, 03080 Alicante, Spain.
1090-3801/97/020161+04 $12.00/O
MATERIALS AND METHODS
Male Swiss-Webster mice (2540 g) were housed in groups of 10 with food and water ad libitum and maintained on a 12/12 h light/dark cycle, with stable humidity and temperature (2%22°C). The ethical standards for the investigation of experimental pain in animals were followed.
All compounds for subcutaneous (s.c.) in- jections (0.25-0.40 ml) were dissolved in normal saline. Morphine hydrochloride was obtained from Alkaliber Lab., Spain, M6G from Ultrafine Chemicals, UK, and M3G from Sigma, USA.
The hot plate test was used to determine the degree of antinociception. The test was performed daily before the injection of the drug (the baseline latency was taken as the mean of two meas- urements, made 30 min apart), and 30 min after administration of morphine or 60 min after M6G (Faura et al., 1996). The mean value + SD of the daily baseline latencies was 10.4 f 1.1 s and the coefficient of variation was 10.6%. Animals with a baseline latency I 6 or 2 14 s were ex- cluded.
Different experiments were performed to study the development of tolerance to 4 mg/kg of M6G (equipotent dose to 10 mg/kg of morphine, Faura et al., 1996) alone and when co-administered with 6 mg/kg of M3G (Table 1). Five groups of mice
0 1997 European Federation of Chapters of the International Association for the Study of Pain
TABL
E 1.
Exp
erim
enta
l de
sign
and
antin
ocice
ptive
ef
fect
in
the
stud
ied
grou
ps
Day
1 Da
y 2
Day
3 Da
y 4
Day
5 Da
y 6
Day
7
Grou
ps
Abso
lute
%
Abso
lute
%
Abso
lute
%
Abso
lute
%
Abso
lute
%
Abso
lute
‘XC
Abso
lute
%
1 71
10
70
5110
50
51
10
50
4110
40
41
10
40
319"
33
.3
7/9a
77
.7
2 01
10
0 01
10
0 O/
IO
0 01
9"
0 O/
l 0
0 81
10
80
M 8
/11
72.7
3
5121
23
.8
5121
23
.8
6120
" 30
51
21
23.8
51
21
23.8
M
6G7I
lO
70
4 81
10
80
8110
80
61
10
60
5110
50
41
9"
44.4
31
8"
37.5
61
8"
75
5 01
11
0 l/I
O"
10
019"
0
o/loa
0
0/10
" 0
719"
77
.7
M6G
, m
orph
ine-6
-gluc
uron
ide;
M,
mor
phine
; Ab
solu
te,
num
ber
of
mice
wi
th
antin
ocice
ptive
ef
fect
/tota
l nu
mbe
r of
mice
st
udie
d.
%,
perc
enta
ge
of a
ntin
ocice
ptio
n.
aSom
e m
ice
exclu
ded
beca
use
base
line
late
ncie
s 16
or
2
14.
MORPHINE METABOLITES AND TOLERANCE 163
were treated daily (s.c.) over a 5-day period, as follows:- Group 1: 4 mg/kg of M6G (n = 10); Group 2: saline (n = 10); Group 3: M3G plus 4 mg/kg of M6G (n =21); Group 4: M3G plus 10 mg/kg of M6G (n = 10); and Group 5: M3G plus saline (n = 11). In Groups 3-5, M3G was administered on a daily basis 8 h before M6G or saline over the 5-day period. On Days 6 and 7, no M3G was administered. On Day 6, in order to assess the degree of cross-tolerance to morphine, 10 mg/kg of morphine (equipotent dose to 4 mg/ kg of M6G) was administered to Groups 1, 2, 4 and 5; animals from Group 3 received either 10 mg/kg of morphine (n = 11) or 4 mg/kg of M6G (n = 10). On Day 7, the morphine dose was doubled (20 mg/kg) in those groups (1 and 4) in which the previous morphine dose (10 mg/kg on Day 6) had not produced a significant degree of antinociception (<40%).
Antinociception was quantified as a two-fold or greater increase in the baseline latency for each individual animal (Faura et al., 1996); The results are expressed as percentage of anti- nociception [(number of mice with anti- nociceptive effect/total number of mice) x 1001. For statistical comparison, the Chi-square test was used in a Statview SE software.
RESULTS
Animals treated with either 4mg/kg of M6G alone (Group 1) or 10 mg/kg of M6G with M3G pretreatment (Group 4), showed a similar anti- nociceptive effect which decreased progressively over the 5 days of treatment (from 70 and 80% on Day 1 to 40 and 44% on Day 5, respectively). When morphine was administered instead of M6G on Day 6 to animals from Groups 1 and 4, the antinociceptive effect was similar to that observed on the previous day (33 and 37.5%, respectively). Doubling the dose of morphine on Day 7 increased the antinociceptive effect (Groups 1 and 4: 78 and 75%, respectively) when compared to Day 6 (Table 1).
In animals treated with 4 mg/kg of M6G with M3G pretreatment (Group 3), the low anti- nociceptive effect produced by M6G did not change over the 5 days of treatment; it ranged
from 24 to 30% antinociception. The ad- ministration on Day 6 of M6G (4 mg/kg) without M3G pretreatment produced an antinociceptive effect (70%) significantly higher 0, I 0.05) when compared with animals chronically treated with 4 mg/kg of M6G (33%, Group l), and similar to that observed in saline-treated animals (Groups 5 and 2: 78 and SO%, respectively). The ad- ministration of 10 mg/kg of morphine on Day 6 produced an antinociceptive effect (73%) similar to that observed on Day 6 with 4 mg/kg of M6G (Table 1).
M3G per se did not modify the hot plate latency time.
DISCUSSION
This study has found that the metabolite M3G administered at doses which significantly reduced M6G-induced antinociception, also prevents de- velopment of tolerance to M6G.
As reported previously (Faura et al., 1996), the effect of 4mg/kg of M6G was reduced by one-third in the presence of M3G, and its full effect was recovered by increasing the M6G dose to 10 mg/kg. In the present study, animals treated with 4mg/kg of M6G alone and with 10 mg/ kg of M6G with M3G pretreatment showed a similarity in acute and chronic antinociceptive effect, and followed a similar development of tolerance to M6G.
Although the antinociceptive effect of 4mg/ kg of M6G administered after M3G is low, it remained relatively constant during the 5-day period, and on Day 5 its effect was similar to that achieved with 4mg/kg of M6G alone or lOmg/kg of M6G with M3G pretreatment (Groups 1 and 4). The administration on Day 6 of morphine (10 mg/) or M6G (4 mg/kg) without M3G pretreatment to the animals from Group 3 produces the full antinociceptive effect, as would be expected from an initial dose of the opioid (e.g. Group 1 on Day 1). The difference in the antinociceptive effect between Days 5 and 6, in animals receiving 5 days M6G (4mg/kg) with M3G (6 mg/kg) pretreatment, followed by either morphine lOmg/kg or M6G 4mg/kg (Group 3), shows the absence of tolerance both to morphine and to M6G. The mechanism for
European Journal of Pain (1997). 1
C. C. FAURA ET AL.
to morphine appear, but if antinociception is
the effects of M3G are not clear, and a phar- macokinetic interaction may not be excluded
reduced (i.e. by the administration of M3G), the
since these glucuronides seem to be handled differently in the body (Van Crugten et al., 1991). According to previous reports (Fernandes et al., 1977), and independently of the mechanism be- hind M3G, it can be speculated that the intensity of drug exposure determines the degree of the effect, and plays an important role in the degree of tolerance achieved. The present results suggest that the effect of M3G on the tolerance to M6G is mainly dependent on its ability to decrease the antinociceptive effect, otherwise M3G would inhibit tolerance to M6G independently of the administered dose, and supports the idea that tolerance development might be dependent upon the initial level of antinociception for a given dose; if the antinociceptive effect of M6G is high, tolerance to M6G and cross-tolerance of M6G
was supported by a project grant (SAF93-0260) from CICYT, Spain.
REFERENCES
Ekblom M, Gardmatk M, Hammarlund-Udenaes M. Phar- macokinetics and pharmacodynamics of morphine-3-glu- curonide in rats and its influence on the antinociceptive effect of morphine. Biopharm Drug Dispos 1993; 14: l-l 1.
Faura CC, Olaso MJ, Garcia Cabanes C, Horga JF. Lack of morphine-6-glucuronide antinociception after morphine treatment. Is morphine-3-glucuronide involved? Pain 1996; 65: 25530.
Fernandes M, Kluwe S, Coper H. Quantitative assessment
curonide-a potent antagonist of morphine analgesia.
of tolerance to and dependence on morphine in mice. Naunyn Schmiedebergs Arch Pharmacoll917; 297: 53-60.
Gong QL, Hender J, Bjijrkman R, Hender T. Morphine-3-
Life Sci 1990; 47: 579-585. Van Crugten JT, Sallustio BC, Nation RL, Somogyi AA.
glucuronide may functionally antagonize morphine-6- glucuronide induced antinociception and ventilatory de- pression in the rat. Pain 1992; 48: 249-255. -’ Smith MT, Watt JA, Cramond T. Morphine-3-glu-
tolerance is prevented.
ACKNOWLEDGEMENTS
Renal tubular transport of morphine, morphine-6-glu- curonide, and morphine-3-glucuronide in the isolated perfursed rat kidney. Drug Metabol Dispos 1991; 19: 1087-1092.
The authors wish to thank Mr. S. Ingham for his critical review of this manuscript. The study
European Journal of Pain (1997), 1
Recommended